Importance of Serum SELDI-TOF-MS Analysis in the Diagnosis of Early Lung Cancer

Abstract

Background: Different methods of diagnosis have been found to be inefficient in terms of screening and early diagnosis of lung cancer. Cancer cells produce proteins whose serum levels may be elevated during the early stages of cancer development. Therefore, those proteins may be recognized as potential cancer markers. The aim of this study was to differentiate healthy individuals and lung cancer cases by analyzing their serum protein profiles and evaluate the efficacy of this method in the early diagnosis of lung cancer. Materials and Methods: 170 patients with lung cancer, 53 under high risk of lung cancer, and 47 healthy people were included in our study. Proteomic analysis of the samples was performed with the SELDI-TOF-MS approach. Results: The most discriminatory peak of the high risk group was 8141. When tree classification analysis was performed between lung cancer and the healthy control group, 11547 was determined as the most discriminatory peak, with a sensitivity of 85.5%, a specificity of 89.4%, a positive predictive value (PPV) of 96.7% and a negative predictive value (NPV) of 62.7%. Conclusions: We determined three different protein peaks 11480, 11547 and 11679 were only present in the lung cancer group. The 8141 peak was found in the high-risk group, but not in the lung cancer and control groups. These peaks may prove to be markers of lung cancer which suggests that they may be used in the early diagnosis of lung cancer.

Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

“…Another relevant aspect is represented by the sample preparation protocols, as standard processing procedures to avoid modification or degradation of protein biomarkers are essential. [93] This issue has been investigated in two studies, [48,50] employing the same MS-technology and type of sample source, but different protocols of protein enrichment and processing. The studies [48,50] identified different proteins present in tumor patients compared to control subjects, underlining that the variability of proteomics results can depend not only on patient differences, but also on the lack of protocol standardization.…”

Platelet proteomics in diagnostic differentiation of primary immune thrombocytopenia using SELDI-TOF-MS

“…This characteristic limits the application of genomics and transcriptomics for platelet study, while rendering proteomics a more suitable approach for evaluating platelets in both physiological and pathological conditions [17][18][19][20]. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) is a powerful technology in proteomic studies and has been explored for screening of various cancer biomarkers and disease diagnosis [21][22][23][24]. With continuous development of MS-based proteomics and protein isolation methodology, the field of platelet proteomics has attracted more and more attention in recent years.…”

Serum protein profiles of patients with lung cancer of different histological types

“…Nevertheless, a number of peaks that we identified, for example, the peaks M/Z 1205and 4279, were not recognized previously. 32,33 This is conceivably due to the different experimental procedures used in the studies. Moreover, the varying approaches in data analysis may also contribute to the difference.…”